Are all drug-eluting stents created equal?

Affiliations

¹ Institut Lorrain du Coeur et des Vaisseaux, CHU de Nancy, Université de Lorraine, F-54500 Vandoeuvre -lès-Nancy, France. Electronic address: edoardo@camenzind-cardio.net.
² Institut Lorrain du Coeur et des Vaisseaux, CHU de Nancy, Université de Lorraine, F-54500 Vandoeuvre -lès-Nancy, France.

Comment

Edoardo Camenzind et al. Lancet. 2018.

. 2018 Oct 6;392(10154):1172-1174.

doi: 10.1016/S0140-6736(18)32334-1. Epub 2018 Sep 22.

¹ Institut Lorrain du Coeur et des Vaisseaux, CHU de Nancy, Université de Lorraine, F-54500 Vandoeuvre -lès-Nancy, France. Electronic address: edoardo@camenzind-cardio.net.
² Institut Lorrain du Coeur et des Vaisseaux, CHU de Nancy, Université de Lorraine, F-54500 Vandoeuvre -lès-Nancy, France.

No abstract available

Comment on

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.
von Birgelen C, Zocca P, Buiten RA, Jessurun GAJ, Schotborgh CE, Roguin A, Danse PW, Benit E, Aminian A, van Houwelingen KG, Anthonio RL, Stoel MG, Somi S, Hartmann M, Linssen GCM, Doggen CJM, Kok MM. von Birgelen C, et al. Lancet. 2018 Oct 6;392(10154):1235-1245. doi: 10.1016/S0140-6736(18)32001-4. Epub 2018 Sep 22. Lancet. 2018. PMID: 30253879 Clinical Trial.